Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus and Indomethacin for Post-ERCP Pancreatitis Prophylaxis
NCT05252754Phase 3Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in acute pancreatitis (AP) comparing Oral Tacrolimus + Indomethacin with Oral Placebo + Indomethacin (2 arms). Primary endpoint: Post ERCP Acute Pancreatitis at 30 days. Started Jan 2023; status: recruiting.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT05252754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252754.